The Deal Register
Database › Equity financing › ZYUS Life Sciences Provides Update on Clinical Trial Progress and…

Equity financing

ZYUS Life Sciences Provides Update on Clinical Trial Progress and Unit Private Placement

Lane
Equity financing
Announced
08 Dec 2025
Province
Saskatchewan
Industry
Healthcare & life sciences
Status
Announced
What the filing says
ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS ), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced a key milestone in its ongoing Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial, with patient enrollment reaching twenty-five percent.
Source

The terms are in the subscriber edition

This transaction carries the consideration.

Subscribe

Compiled from public filings, court documents, exchange bulletins and issuer releases. Figures are as disclosed and are not independently verified.

Not financial, investment, legal or tax advice, and not an offer to buy or sell any security. Verify everything before you transact.

The Deal Register · Archive · Subscribe